AF
AARD

Allworth Financial’s Aardvark Therapeutics AARD Stock Holding History

Allworth Financial’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$781 Buy
+207
New +$2.15K ﹤0.01% 4636

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Allworth Financial's AARD Position: Q1 2026 in Review

Allworth Financial opened a new position in Aardvark Therapeutics (AARD) in Q1 2026: 207 shares worth $781. The stake represents ﹤0.01% of the portfolio and ranks #4636 among its holdings.

79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Allworth Financial held 207 shares of Aardvark Therapeutics worth $781 as of Q1 2026.
  • Aardvark Therapeutics was a new Allworth Financial position in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4636 holding.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.